XGN
What one share of Exagen holds
Services – Medical Laboratories
We are a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of innovative testing products under our AVISE® brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Exagen’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.01 |
|---|---|
| Profit | −$0.80 |
| Capex (buildings and equipment) | $0.05 |
| Free cash flow | −$0.32 |
| Cash and investments | $1.02 |
| Debt | $1.06 |
| Book value | $0.50 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $514.88 | −$293.34 | $3.16 | −$150.78 | — | −$1,777 |
| 2019 | $11.29 | −$8.46 | $0.11 | −$2.83 | — | — |
| 2020 | $3.32 | −$1.32 | $0.04 | −$1.15 | — | $3.31 |
| 2021 | $3.02 | −$1.68 | $0.15 | −$1.42 | — | $5.25 |
| 2022 | $2.67 | −$2.77 | $0.25 | −$2.13 | — | $2.57 |
| 2023 | $2.97 | −$1.34 | $0.05 | −$0.86 | — | $1.33 |
| 2024 | $3.06 | −$0.83 | $0.03 | −$0.76 | — | $0.54 |
| 2025 | $3.09 | −$0.93 | $0.03 | −$0.66 | — | $0.76 |